Spirulina and Specialized Pro-Resolving Mediators

SPMs: The Resolution Program

Specialized pro-resolving mediators (SPMs) are lipid signaling molecules derived from omega-3 fatty acids that actively drive inflammation resolution. Families include resolvin E series (from EPA), resolvin D series (from DHA), protectins (from DHA), and maresins (macrophage-derived from DHA). They are biosynthesized via 15-lipoxygenase (15-LOX), 5-LOX, COX-2 in resolving (not inflammatory) mode, and CYP enzymes.

Resolution vs Anti-Inflammation

Classical NSAIDs and steroids suppress inflammation by blocking pro-inflammatory mediator synthesis. SPMs work differently — actively driving macrophage efferocytosis (clearing apoptotic cells), promoting neutrophil apoptosis, and shifting macrophage polarization toward M2. Resolution requires SPM "turn on," not just inflammation "turn off."

EPA/DHA Substrate Provision

SPM biosynthesis requires adequate EPA and DHA substrate. Western diets are typically DHA/EPA-poor, limiting SPM production capacity. Spirulina contains modest GLA and ALA but minimal direct EPA/DHA. However, AMPK-mediated SIRT3 activation in macrophages enhances 15-LOX activity, increasing SPM yield per unit substrate by 20–35%.

Macrophage Class Switching

SPMs drive macrophage class switching from inflammatory M1 to resolution-phase M2 phenotype (covered separately as M1/M2). This switch enables efferocytosis — clearing apoptotic neutrophils that would otherwise undergo secondary necrosis releasing DAMPs. Spirulina's direct M2-polarizing effects synergize with SPM biology.

Chronic Inflammation as Resolution Failure

Many chronic inflammatory conditions reflect failed resolution rather than excess inflammation initiation. Atherosclerosis, asthma, periodontitis, and inflammatory bowel disease all show SPM deficiency. Spirulina's combined effects on inflammation initiation (NF-κB), amplification (NLRP3), and resolution (SPM-supportive via 15-LOX) address multiple regulatory layers.

Lipoxin A4: The Aspirin-Triggered Mediator

Lipoxin A4 (LXA4) is a SPM derived from arachidonic acid via 15-LOX and 5-LOX. Aspirin acetylates COX-2 to produce 15R-HETE that converts to aspirin-triggered LXA4. LXA4 binds FPR2/ALX receptor, driving resolution. Spirulina enhances LXA4 production through 15-LOX activity preservation, providing aspirin-mimetic resolution-promoting effects.

Conclusion

Spirulina supports active inflammation resolution through enhanced SPM biosynthesis (20–35% increase in 15-LOX-dependent SPM yield), M2 macrophage polarization supporting efferocytosis, and lipoxin A4 production providing aspirin-mimetic resolution. Combined with its better-known anti-inflammatory effects, this dual inflammation/resolution intervention is mechanistically distinct from classical NSAIDs — actively driving resolution rather than just blocking inflammation generation. Particularly relevant for chronic inflammatory conditions reflecting failed resolution.